Sahlgrenska University Hospital first Swedish site in the largest ever prospective clinical study for early detection of pancreatic cancer
LUND and Gothenburg, Sweden ― Immunovia AB today announced that Sahlgrenska University Hospital is the first Swedish site to be part of PanFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study which started one year ago at Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid, Spain, will analyze thousand individuals for three years across sites in both the US and Europe offering FPC screening programs, and will open up the market and sales for testing hereditary pancreatic cancer patients.
“For 7 years, we have been conducting a surveillance program for familiar pancreatic cancer high risk individuals in our center,” says Svein Olav Bratlie, Head of the section for Pancreatic Surgery, at Sahlgrenska University Hospital. “It is obvious that early detection can lead to successful surgical intervention and consequently to better patient management. For this reason, an accurate, reliable and highly sensitive blood based test would be necessary. We are delighted to begin the prospective validation of IMMrayTM PanCan-d in Sweden as part of our surveillance program of familiar pancreatic cancer high risk individuals and we are looking forward to the results.”
“We are very pleased to work with Sahlgrenska University Hospital for PanFAM-1 clinical study. This collaboration will not only support the multicenter prospective validation of IMMray TM PanCan-d but will also play a critical role in providing us data and clinical evidence for regulatory and reimbursement application of the test in Sweden.“ commented Mats Grahn, CEO, Immunovia.
Pancreatic cancer continues to have one of the lowest survival rates of any major cancer type. It is widely acknowledged, that the key to improving prognosis and possible successful surgical intervention lies in early detection. Following years of research, Immunovia has developed the first blood based biomarker test to be validated in FPC high risk individuals undergoing annual screening for early pancreatic cancer detection.
The other PanFAM-1 partners to date are: Mount Sinai in New York, Knight Cancer Institute at Oregon Health and Sciences University, Portland, USA, the University of Liverpool, UK and Ramon y Cajal Institute for Health Research, Madrid, Spain. Immunovia is also in advanced discussions with several other high risk surveillance programs from Europe and USA about their participation.
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.